RecruitingNot ApplicableNCT06214988

Selective Defunctioning Stoma in Low Anterior Resection for Rectal Cancer

SELective Defunctioning Stoma Approach in Low Anterior Resection for Rectal Cancer (SELSA): a Prospective Study With a Nested Randomised Clinical Trial


Sponsor

Skane University Hospital

Enrollment

212 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this observational trial with a nested randomized controlled trial is to investigate a selective approach of defunctioning stoma in low anterior resection in rectal cancer patients. The primary outcome is a hybrid so-called textbook outcome; stoma-free survival at two years without major LARS, reflecting a functionally appropriate outcome after low anterior resection for rectal cancer. Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma-related complications, quality of life measures, LARS, and permanent stoma rate up to two years after index surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Adult patients with rectal cancer planned for a low anterior resection with anastomosis by TME with any surgical approach
  • Patients aged less than 80 years
  • Patients with American Society of Anesthetists' (ASA) fitness grade I or II as determined by the anaesthesiologist or the surgeon
  • Patients without clear radiological signs of distant disease before rectal cancer surgery (previous metastatic surgery is no exclusion criterion)
  • Anastomotic leak risk score of 0-1
  • Willingness to be randomised

Exclusion Criteria16

  • Insufficient command of Swedish, Norwegian, Danish or English to understand questionnaires or consent
  • Emergency rectal resection (tumour resection due to large bowel obstruction, perforation, etc)
  • Previous pelvic irradiation (due to e.g. gynaecological or urological cancer)
  • Preoperative tumour perforation or pelvic sepsis
  • Beyond TME surgery and/or concurrent resection of other organ
  • Concurrent corticosteroid treatment (prednisone-equivalent dosage ≥10 mg daily)
  • Planned postoperative chemotherapy
  • Smoking not completely ceased four weeks before surgery
  • \>2 staple firings for rectal transection
  • Intraoperative blood loss ≥250 ml for minimally invasive surgery
  • Intraoperative blood loss ≥500 ml for open or converted surgery
  • More than one intraabdominal anastomosis performed
  • Incomplete doughnuts
  • Air-leak test positive
  • Any significant intraoperative adverse event at the discretion of the operating surgeon (e.g. ureterotomy, bowel or tumour perforation, major medical event - pulmonary embolism, cardiac arrhythmia) (Gawria, 2022)
  • TME with anastomosis ultimately not done

Interventions

PROCEDUREselective approach defunctioning stoma

With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.


Locations(1)

Skåne University Hospital

Malmo, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06214988


Related Trials